Saeedeh Farajzadeh; Soodabeh Zandi; Mohammad Mehdi Hayatbaksh Abbasi; Fahimeh Gadari; Armita Shahesmaeili; Behrooz Vares; Golamreza Hosseinpour; Iman Shojaei Baghini
Volume 14, Issue 3 , 2011, , Pages 81-85
Abstract
Background: The association between coronary artery disease and androgenic alopecia has been demonstrated, but few studies have focused on the mechanism of this association. The aim of this study was to evaluate the lipid profile in male pattern alopecia.Methods: In this case control study, 45 male patients ...
Read More
Background: The association between coronary artery disease and androgenic alopecia has been demonstrated, but few studies have focused on the mechanism of this association. The aim of this study was to evaluate the lipid profile in male pattern alopecia.Methods: In this case control study, 45 male patients with androgenic alopecia who were aged from 20 to 50 years and 45 men with a normal hair status aged from 20 to 50 years were enrolled as the case and control groups, respectively. Lipid parameters including cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, lipoprotein (a), apolipoprotein A1, apolipoprotein B were measured in cases and controls.Results: A significant difference in serum lipoprotein (a) was observed between case and control groups (p< 0.001). We noted that 47.1 percent of the patients and 17.96% of the controls had a lipoprotein (a) level more than 30 mg/dl which is a critical level for coronary artery disease. There was no significant difference in other lipid parameters between two groups. The family history of androgenic alopecia and coronary heart disease was significantly higher in the cases than the controls.Conclusion: Considering the results of the study and the important role of lipoprotein (a) as a risk factor for atherosclerotic heart disease, we suggest that all men with a male pattern hair loss should be investigated for lipid indices, especially lipoprotein (a).
Simin Shamsi Meymandi; Manzumeh Shamsi Meymandi; Soodabeh Zandi; Shahriar Dabiri; Mahin Aflatoonian
Volume 14, Issue 2 , 2011, , Pages 42-47
Abstract
Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy ...
Read More
Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. Method: This is a prospective, randomized, open trial study (from Iran) from September 2008 to September 2010, including 50 patients (25 patients in the combined imiquimod and cryotherapy group and 25 patients in the intralesional MA group). Patients were randomly assigned to receive combined cryotherapy biweekly with imiquimod three times per week or intralesional MA weekly until complete cure or up to 12 weeks, whichever earlier. The primary end point was clinical cure, defined as complete re-epitelialization of 100%, complete flattening of induration compared with baseline at weeks 2, 6, 12 and follow up were done 1, 2 and 3 months after complete cure. Results: 50 participants divided into 25 patients in group A and 25 patients in group B completed the study. Complete cure was 65.5% (16/24 patients) in group A and 83.3% (19/23 patients) in group B. No complication was detected in patients treated with MA. Pain and eczematous reaction were detected by 4 patients and local infection in 1 patient treated with imiquimod. Conclusion: Although Meguimine antimoniate seems to be a more effective therapy for cutaneous leishmaniasis, this study revealed no significant difference in clinical response between combination of imiquimod and cryotherapy with intralesional MA in patients with cutaneous leishmaniasis in an endemic area of L. tropica.